# A Study of FX-909 in Patients With Advanced Solid Malignancies, Including Advanced Urothelial Carcinoma

Source: https://onco.cc/trials/nct05929235/  
OnCo record `nct05929235` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1 trial of FX-909 run by Flare Therapeutics Inc., active, not recruiting.

## Summary

A Study of FX-909 in Patients With Advanced Solid Malignancies, Including Advanced Urothelial Carcinoma is a phase 1 interventional study registered as NCT05929235 by Flare Therapeutics Inc., with 120 participants planned, started 2023-08-24, primary completion expected 2027-10-30. Conditions recorded: Advanced Urothelial Carcinoma, Oral Drug Administration, Open Label. Interventions recorded: FX-909, Pembrolizumab (KEYTRUDA ®), KEYTRUDA ®( Pembrolizumab).

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-11-04
- Tags: pipeline; ctgov-ingest
- Registry id: NCT05929235
- Phase: 1
- Setting: A Phase 1, First-in-Human, Dose-Escalation and Expansion Study of FX-909 (as Monotherapy or in Combination With Pembrolizumab) in Patients With Advanced Solid Malignancies, Including Advanced Urothelial Carcinoma
- Sponsor: Flare Therapeutics Inc.
- Enrolled: 120

## Sources

- ClinicalTrials.gov NCT05929235: https://clinicaltrials.gov/study/NCT05929235

## Connected records

- cancers: [Bladder & urothelial cancer](https://onco.cc/cancers/urothelial/)
- drugs: [FX-909](https://onco.cc/drugs/fx-909/)
- companies: [Flare Therapeutics](https://onco.cc/companies/flare-therapeutics/)

---
JSON: https://onco.cc/api/v1/entities/nct05929235.json